AgingResearch.NewsJoin free

Revolution

CompanyUnited States

Revolution develops one asset, in phase 3 (daraxonrasib in metastatic RAS G12D pancreatic adenocarcinoma). Mostly other acting on KRAS, NRAS and HRAS; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • daraxonrasib

    RAS(ON) multi-selective inhibitor

    Phase 3, Other, KRAS, NRAS, metastatic RAS G12D pancreatic adenocarcinoma, metastatic RAS G12D pancreatic cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals2
  • Integrity notices1
  • Similar companies6

Intelligence